Invion (AU:IVX)
ASX:IVX
Want to see AU:IVX full AI Analyst Report?
IVX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.20
Previous CloseN/A
Volume36.17K
Average Volume (3M)97.01K
Market Cap
AU$4.95M
Enterprise ValueAU$5.53M
Total Cash (Recent Filing)AU$137.54K
Total Debt (Recent Filing)AU$627.68K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding96,965,320
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage — No Reported DebtThe absence of reported debt materially reduces fixed financing costs and interest exposure, giving management flexibility to prioritize R&D and partnership deals. For a cash-burning biotech, no debt lowers near-term insolvency risk and preserves optionality for strategic funding or licensing choices over months.
Partnership-driven Funding And Licensing ModelA business model centered on partner-funded R&D and milestone/licensing fees transfers development risk and capital needs to collaborators. This durable funding channel can extend runway, align incentives with larger partners, and enable progression of programs without immediate product revenue dependency.
Proprietary PDT Focus With Institutional CollaborationsSpecialization in photodynamic therapy and formal research collaborations create a focused IP and expertise base. Over time this can produce high barriers to entry, attract follow-on funding or licensing, and create a defendable niche in oncology/respiratory treatment development if clinical progress is demonstrated.
Bears Say
Zero Revenue And Widening Net LossesA collapse to zero revenue alongside a materially larger net loss signals the company cannot currently monetize its assets or convert R&D into sales. Persisting negative margins erode capital and force continued external financing, reducing the firm's ability to self-fund development and increasing long-term dilution risk.
Persistent Negative Operating Cash Flow And Cash BurnConsistent operating outflows and negative free cash flow indicate the business cannot generate internal funding for operations or trials. Over a multi-month horizon this necessitates external capital raises or partner funding, which can dilute shareholders, constrain strategic choices, and limit sustained R&D investment cadence.
Shrinking Equity And Asset Base Reduces FlexibilityA materially declining equity and asset base weakens the balance sheet cushion available for losses or investment. Reduced financial flexibility makes future fundraising more dilutive or difficult, lowers bargaining power with partners, and heightens long-term solvency concerns if losses persist.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.05 and its highest was AU$0.20 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$4.95M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -AU$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.042.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IVX Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is dedicated to advancing its novel technologies to offer innovative treatment solutions that can improve patient outcomes. The company's core products include its proprietary PDT compounds and related systems that leverage light-activated processes to target and destroy cancer cells.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Options Prices
Currently, No data available
---